{"owner": "ArrayExpress Uploader", "pop_total": 0, "id": 6288, "factors": [{"GSM632859": {"DISEASE STATUS": "failing, atherosclerosis", "GENOTYPE/VARIATION": "apoE-deficient"}}, {"GSM632859": {"DISEASE STATUS": "failing, atherosclerosis", "GENOTYPE/VARIATION": "apoE-deficient"}}, {"GSM63286": {"DISEASE STATUS": "control", "GENOTYPE/VARIATION": "wild type"}}, {"GSM63286": {"DISEASE STATUS": "control", "GENOTYPE/VARIATION": "wild type"}}, {"GSM632879": {"DISEASE STATUS": "atherosclerosis", "GENOTYPE/VARIATION": "apoE-deficient"}}, {"GSM632879": {"DISEASE STATUS": "atherosclerosis", "GENOTYPE/VARIATION": "apoE-deficient"}}], "ownerprofile_id": "arrayexpress_sid", "platform": 6, "summary_wrapped": "Heart failure is a leading cause of cardiovascular mortality with limited options for treatment. We used 18 month-old apolipoprotein E...", "geo_gse_id": "E-GEOD-25767", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 2, "sample_count": 6, "tags": ["atherosclerosis", "heart"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "cardiac-gene-expression-profiling-of-apoe-deficien", "geo_id_plat": "E-GEOD-25767_A-AFFY-45", "name": "Cardiac gene expression profiling of apoE-deficient mice receiving heart failure treatment with the anti-ischemic drug ranolazine", "created": "Nov.11, 2014", "summary": "Heart failure is a leading cause of cardiovascular mortality with limited options for treatment. We used 18 month-old apolipoprotein E (apoE)- deficient mice as a model of atherosclerosis-induced heart failure to analyze whether the anti-ischemic drug ranolazine could retard the progression of heart failure. The study showed that 2 months of ranolazine treatment improved cardiac function of 18 month-old apoE-deficient mice with symptoms of heart failure as assessed by echocardiography. To identify changes in cardiac gene expression induced by treatment with ranolazine a microarray study was performed with heart tissue from failing hearts relative to ranolazine-treated and healthy control hearts. The microarray approach identified heart failure-specific genes that were normalized during treatment with the anti-ischemic drug ranolazine. Microarray gene expression profiling was performed with heart tissue isolated from (i) untreated 18 month-old apoE-deficient mice with heart failure relative to (ii) 18 month-old apoE-deficient mice treated for two months with the anti-ischemic drug ranolazine (200 mg/kg), and (iii) age-matched non-transgenic C57BL/6J (B6) control mice.", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-25767", "species": "mouse", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-25767/samples/"}